Keyword: Eli Lilly

Emgality will likely chase Amgen and Novartis’ first-in-class Aimovig and Teva's Ajovy in the CGRP migraine field.

As it works to turn its business around, Teva picked up an important FDA approval for migraine prevention medication Ajovy.

AndroGel plaintiffs and drugmaker AbbVie have progressed in settlement talks, and a judge stayed further proceedings so they can work out a deal.

Aurobindo buys parts of Sandoz for $1B; an ex-GSK scientist admits to stealing trade secrets; Lilly and Chi-Med's Chinese-made drug makes history.

China, which has been waving through cancer drugs made by multinational pharmas, can now count a homegrown one among its approvals.

With oncology head Sue Mahony retiring Friday, Eli Lilly has her replacement ready to step in.

The FDA has raised red flags about a potentially serious flesh-eating disease in patients taking SGLT2 inhibitors.

After HHS proposed a rule that would shake up or eliminate drug rebates, a watchdog wants to know if agency chief Alex Azar has ulterior motives.

Amgen's migraine drug Aimovig is riding a big wave of early demand, and those launch trends spell good things for its forthcoming rivals.

The FDA is moving closer to kicking off two proposed studies around drug advertising risk information and disclosures.